DescriptionHow to take?CommonSide EffectsLatest New'sPhoto's
Naltrexone is used to prevent relapse in people who became dependent on opioid medicine and then stopped using it. Naltrexone can help keep you from feeling a “need” to use the opioid.
Generic Revia can be ordering online via contact form of website: wemailmd.com, shipping availalbe from India via two differents way, for future details about how to order Naltexone, please, contact our support team using request page.
Naltrexone in India, made by manufacturer Intas (est: 1993), available in dosages 50mg each tablet.
Naltrexone should not be used to treat people who are still using street drugs or drinking large amounts of alcohol. Naltrexone is in a class of medications called opiate antagonists. It works by decreasing the craving for alcohol and blocking the effects of opiate medications and opioid street drugs.
If naltrexone is taken at home, it is usually taken once a day with or without food. it may be taken once a day, once every other day, once every third day, or once every day except Sunday. Please folow the instruction on your prescription label carefully, and speak with your doctor to explain any part you do not understand. Do not take more or less of it or take it more often than prescribed by your doctor.
Naltrexone is only helpful when it is used as part of an addiction treatment program.
Upset stomach or vomiting
Diarrhea
Headache
Nervousness
Sleep problems/tiredness
Joint or muscle pain
Analysis and Forecast To 2025
In order to identify growth opportunities in the market, the report has been segmented into regions that are growing faster than the overall market. These regions have been potholed against the areas that have been showing a slower growth rate than the market over the global. Each geographic segment of the Naltrexone HCL market has been independently surveyed along with pricing, distribution and demand data for geographic market notably: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).
FDA urged to probe naltrexone implant tests on prison inmates
The FDA is being urged to investigate California biotech BioCorRx amid claims that it tested an unapproved drug implant for dependency on prison inmates without institutional oversight or thoroughly gathered legal consent.
The advocacy group Public Citizen said a pilot project at the company—originally planned for 10 inmates housed within the Louisiana prison system—involved a long-lasting formulation of the anti-addiction therapy naltrexone as a biodegradable implant that slowly releases the drug over 90 days. Naltrexone has previously received U.S. approvals for treating opioid and alcohol dependence as a tablet and injection.
The project was ended soon after it was announced in May following criticism, according to Public Citizen—but the group says BioCorRx may still be conducting trials elsewhere in the U.S. that may be in violation of regulations governing testing in human subjects.
“Naltrexone implants have been utilized by countless medical doctors under their discretion with their patients for over 20 years in the U.S. under the constantly changing pharmacy compounding guidance and from several licensed compounding pharmacies; long before the existence of some researching group” the company added.
Is naltrexone safe for pregnant patients?
Published in the American Journal and Obstetrics & Gynecology, the data are from a cohort of 230 patients taking MAT, 121 of whom were given naltrexone and 109 of whom were given methadone or buprenorphine. The authors looked at the rate of newborns treated for symptoms of neonatal abstinence syndrome (NAS). In a subset of 20 random patients on naltrexone, they also assessed maternal and newborn blood levels of naltrexone and 6-beta-naltrexol at delivery.
In the study, the daily dosage range was 8 to 16 mg for buprenorphine and 50 to 120 mg for methadone. Patients on naltrexone must have been opioid-free for at least 7 days and have had two negative drug screens before taking the drug. The daily oral dosage was 50 mg.
At ≥ 24 weeks’ gestation, fetal heart rate (FHR) monitoring was done for ≥ 60 minutes while the initial naltrexone dose was administered. At < 24 weeks, the FHR was evaluated with Doppler or ultrasound imaging before the first dose, 30 minutes after dosing, and again at 60 minutes. Biophysical profiles were done on all the patients every other week from 28 to 32 weeks’ gestation and weekly thereafter until delivery.
